Layoff sprees at Amarin, FibroGen, Boston Scientific

Today's Big News

Jul 19, 2023

Pfizer spies cardiovascular potential in Riparian preclinical licensing agreement


GSK-funded report on adult vaccination rates found major global declines in recent years


Medtronic recalls thousands of implantable defibrillators that may deliver less-powerful shocks


Amarin axes 120 of its 385 employees, hires new CEO Patrick Holt


FibroGen’s cost-cutting search spurs 104 layoffs, while ImmuneID also restructures

 

Featured

Pfizer spies cardiovascular potential in Riparian preclinical licensing agreement

Pfizer has licensed a preclinical cardiovascular program from Riparian Pharmaceuticals as part of an agreement that will also see the Big Pharma support further discovery efforts by the biotech.
18-19
Jul
July 18-19, 2023 | Jersey City, NJ
 

Top Stories

GSK-funded report on adult vaccination rates ⁠finds major global declines in recent years

The GSK-funded report looked at adult vaccination data and found a major slump in vaccine adoption over the last few years, save for COVID vaccines.

Medtronic recalls thousands of implantable defibrillators that may deliver less-powerful shocks

Medtronic has found that some of its cardiac implants may deliver either low-energy shocks or none at all even when they’ve been programmed to deliver high-voltage therapy.

Amarin axes 120 of its 385 employees, hires new CEO Patrick Holt

Amarin is restructuring under new leadership following a takeover of its board by activist investor Sarissa Capital three months ago. The company will lay off its entire sales force in the United States and reduce its non-sales staff by 30%. Amarin also has hired a new CEO, Patrick Holt.

FibroGen's cost-cutting search spurs 104 layoffs while ImmuneID also restructures

FibroGen's previously announced cost-cutting plans are taking shape, with the biotech announcing layoffs affecting 32% of its team. Arch-backed ImmuneID is also laying off staff to help push a lead asset into the clinic.

Boston Scientific lays off 52 workers as it closes another Silicon Valley facility

Boston Scientific will permanently close a facility in the San Francisco Bay Area, resulting in the layoffs of dozens of workers there.

Obesity drug shortage expands to Saxenda as Novo Nordisk warns of limited supply for 2023 and beyond

After Novo Nordisk's Wegovy became hard to come by, people turned to the company first-generation weight loss drug, Saxenda, for treatment. Now, the company is struggling to handle demand for that product.

FDA clearance opens up MeMed's bacteria-versus-virus blood test to the point-of-care

The infectious disease diagnostic company MeMed is taking a big step toward a larger market, courtesy of an FDA green light for its test that distinguishes between viral and bacterial cases.

Regulatory tracker: Ipsen's palovarotene rejected by European Commission in ultra-rare disease

In this tracker, Fierce Pharma is recording the regulatory progress of in-market products, including expansions into key geographies and new indications. Some of these updates may not meet the bar for standalone stories, but we think they are still worth mentioning.
 
Fierce podcasts

Don't miss an episode

'The Top Line': New HIV therapies, plus this week's headlines

This week on "The Top Line," we discuss new HIV therapies, plus Humira's new biosimilar, foreign pharmaceutical investments, and the rest of the week's headlines.
 

Resources

Whitepaper

Five ways to get the most from your lab and manufacturing facilities

Leading facilities practices and technologies can help improve the productivity of your research and manufacturing operations—and accelerate the journey from laboratory to saving lives.
Webinar

Novel Antibodies for the Characterization of CAR-T Cells

Download this webinar to learn how to avoid pitfalls when characterizing CAR-T cells in your development workflow, how to save time by using one antibody to examine your entire panel of CARs, and more.
Whitepaper

Improving the Patient Experience Through Research-Driven Design

Learn more about the current challenges and issues that eClinical technology providers are facing.
Research

Develop a cost-effective cGMP chemical sourcing strategy

The right sourcing strategy can help save of millions of dollars—learn about developing a strategy for sourcing the cGMP chemicals critical to your processes.
Whitepaper

Discovering High-Affinity, Functional Anti-GLP-1R Antibodies

Learn how a GPCR-focused library with a cell-based biopanning strategy led to the discovery of 13 high-affinity and selective anti-GLP-1R antibodies with highly developable therapeutic properties.
eBook

Medical Affairs Metamorphosis

This eBook identifies the trends driving major change in the Medical Affairs (MA) function. It also outlines the strategic and tactical implications for MA leaders and team members.
eBook

6 Tools Trial Sponsors Need to Take Action Earlier in Enrollment

Take a look at the reporting tools sponsors need to access insights earlier in the clinical trial enrollment funnel, so you can take informed actions.
Whitepaper

Enhance the cost-effectiveness of your GMP chemical supply chain

Learn how to develop a high-performing supply chain for cGMP chemicals used throughout your bioprocessing workflows.
 

Industry Events

 

Upcoming Fierce Events

18-19
Jul
July 18-19, 2023 | Jersey City, NJ
11-14
Sep
Philadelphia, PA
13
Sep
Philadelphia, PA
19-21
Sep
Virtual Event
26-28
Sep
Philadelphia, PA

View all events